Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
ICMR will continue to track trends in HMPV circulation throughout the year
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Subscribe To Our Newsletter & Stay Updated
